| 3.81 -0.13 (-3.3%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.73 |
1-year : | 5.48 |
| Resists | First : | 4.05 |
Second : | 4.69 |
| Pivot price | 4.02  |
|||
| Supports | First : | 3 | Second : | 2.49 |
| MAs | MA(5) : | 4.05 |
MA(20) : | 3.9 |
| MA(100) : | 7.16 |
MA(250) : | 23.31 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 42.3 |
D(3) : | 56.8 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 104 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SHPH ] has closed above bottom band by 30.8%. Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.01 - 4.03 | 4.03 - 4.05 |
| Low: | 3.64 - 3.66 | 3.66 - 3.68 |
| Close: | 3.77 - 3.81 | 3.81 - 3.84 |
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Tue, 24 Jun 2025
Shuttle Pharmaceuticals Secures $4.25M Private Placement: Major Expansion Plans Revealed - Stock Titan
Tue, 24 Jun 2025
Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market - GlobeNewswire
Fri, 20 Jun 2025
Shuttle Pharmaceuticals Raises $4.25M to Accelerate Cancer Radiation Therapy Breakthroughs - Stock Titan
Thu, 12 Jun 2025
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative - GlobeNewswire
Thu, 12 Jun 2025
Shuttle Pharma Board Approves Major 25:1 Reverse Split to Maintain Nasdaq Listing - Stock Titan
Thu, 15 May 2025
Shuttle Pharma Provides Corporate Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 28 (K) |
| EPS | -69.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.86 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -115.1 % |
| Return on Equity (ttm) | -346.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -20.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|